Hosted on MSN1mon
AbbVie acquires Nimble Therapeutics to boost R&DAbbVie (NYSE: NYSE:ABBV), a global biopharmaceutical ... has announced the completion of its acquisition of Nimble Therapeutics, a move aimed at strengthening its research and development pipeline ...
Hosted on MSN2mon
AbbVie to acquire Nimble Therapeutics for $200mAbbVie has agreed to acquire Nimble Therapeutics for $200m in cash at closing, subject to standard adjustments, alongside potential interim funding payments. The acquisition includes Nimble's ...
Jan. 23, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Nimble Therapeutics. With the completion of the acquisition, Nimble is now a part of AbbVie.
Under the leadership of Rob Michael, AbbVie continues to make tremendous progress in developing its immunology and ...
AbbVie has agreed a $200 million-plus takeover deal with Roche spinout Nimble Therapeutics that will give it control of a preclinical-stage, oral drug for psoriasis. US-based Nimble was set up in ...
Last month, AbbVie completed its acquisition of Nimble Therapeutics, and it also announced a partnership with Simcere Zaiming and expanded its collaboration with AbCellera. A stock popular with ...
AbbVie signs heavily backloaded $2.1B Xilio biobucks pact in Big Pharma's latest T-cell engager deal
Having kicked off the year with a T-cell engager deal, AbbVie has returned to the modality. | Having kicked off the year with ...
In a separate development, AbbVie has completed the acquisition of Nimble Therapeutics, which is now integrated into AbbVie's operations. The oral peptide interleukin 23 receptor (IL23R ...
The North Chicago drugmaker says it could pay Xilio Therapeutics more than $2.1 billion in a collaboration and ...
AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results